VEGFC overexpression in tumors induces a stronger immune response followed by the application of anti-PD-1 or anti-CTLA-4 treatment, in which the tumors displayed decreased tumor volumes and tumor weight and showed longer survival compared to the Vector group in the mice (44). This evidence concerns the gene CTLA4 and neoplasm.